| Name | Title | Contact Details |
|---|---|---|
Mike Dunlop |
Senior Director, Talent Acquisition - Commercial & Corporate Functions | Profile |
Ben Lemelin |
Global People BP Head | Profile |
Ryan Burger |
VP, Global Head of Procurement Services | Profile |
Michael Redd |
Director Customer Supply Chain | Profile |
Laura Grandis |
Head of National Sales, CardioMetabolic | Profile |
Our proprietary and vertically integrated technology solutions empower clients to improve patient outcomes and enhance medication adherence through improved access (virtual care and MTM), owned pharmacy infrastructure and physician network, information...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation`s leading ophthalmology outsourcing facility and pharmaceutical compounding business.
Pace Alliance is a Lawrence, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.